Law360, New York (August 24, 2007, 12:00 AM ET) -- Bayer AG may soon face regulatory scrutiny over Trasylol, with the U.S. Food and Drug Administration set to hear testimony from a group of outside experts as to whether the blood-clotting drug can cause kidney damage, heart failure and even death.
The FDA's Cardiovascular and Renal Drugs Advisory Committee and its Drug Safety and Risk Management Advisory Committee are scheduled to review Trasylol's safety at a meeting slated for Sept. 12, the agency said on Wednesday.
The committees will discuss clinical data for Trasylol, or aprotinin...
Trasylol Continues To Cause Heartache For Bayer
To view the full article, take a free trial now.
